What is the optimal therapy for childhood AML?

David M. Loeb, Robert J. Arceci

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

The use of intensive therapy overa brief period of time has produced dramatic improvements in outcome for pediatric patients with acute myelogenous leukemia (AML), as has been demonstrated in studies by the major cooperative groups in the United States and Europe. Still, despite high-intensity chemotherapy and bone marrow transplantation, only about half of the children diagnosed with AML are cured. Future improvements are unlikely to come from further increases in chemotherapy intensity. Alternative approaches, such as risk-directed therapy based on different prognostic criteria; differentiation therapy with all-trans-retinoic acid (ATRA, Vesanoid), arsenic trioxide (Trisenox), or azacytidine; and immunotherapy with monoclonal antibodies, tumor vaccines, or cytokines may lead to further advances.

Original languageEnglish (US)
Pages (from-to)1057-1066
Number of pages10
JournalOncology (Williston Park, N.Y.)
Volume16
Issue number8
StatePublished - Aug 1 2002
Externally publishedYes

Fingerprint

Acute Myeloid Leukemia
Tretinoin
Azacitidine
Drug Therapy
Cancer Vaccines
Bone Marrow Transplantation
Immunotherapy
Therapeutics
Monoclonal Antibodies
Pediatrics
Cytokines
arsenic trioxide

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

What is the optimal therapy for childhood AML? / Loeb, David M.; Arceci, Robert J.

In: Oncology (Williston Park, N.Y.), Vol. 16, No. 8, 01.08.2002, p. 1057-1066.

Research output: Contribution to journalReview article

Loeb, David M. ; Arceci, Robert J. / What is the optimal therapy for childhood AML?. In: Oncology (Williston Park, N.Y.). 2002 ; Vol. 16, No. 8. pp. 1057-1066.
@article{1e2951c23c284e989a754dc018db0362,
title = "What is the optimal therapy for childhood AML?",
abstract = "The use of intensive therapy overa brief period of time has produced dramatic improvements in outcome for pediatric patients with acute myelogenous leukemia (AML), as has been demonstrated in studies by the major cooperative groups in the United States and Europe. Still, despite high-intensity chemotherapy and bone marrow transplantation, only about half of the children diagnosed with AML are cured. Future improvements are unlikely to come from further increases in chemotherapy intensity. Alternative approaches, such as risk-directed therapy based on different prognostic criteria; differentiation therapy with all-trans-retinoic acid (ATRA, Vesanoid), arsenic trioxide (Trisenox), or azacytidine; and immunotherapy with monoclonal antibodies, tumor vaccines, or cytokines may lead to further advances.",
author = "Loeb, {David M.} and Arceci, {Robert J.}",
year = "2002",
month = "8",
day = "1",
language = "English (US)",
volume = "16",
pages = "1057--1066",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "8",

}

TY - JOUR

T1 - What is the optimal therapy for childhood AML?

AU - Loeb, David M.

AU - Arceci, Robert J.

PY - 2002/8/1

Y1 - 2002/8/1

N2 - The use of intensive therapy overa brief period of time has produced dramatic improvements in outcome for pediatric patients with acute myelogenous leukemia (AML), as has been demonstrated in studies by the major cooperative groups in the United States and Europe. Still, despite high-intensity chemotherapy and bone marrow transplantation, only about half of the children diagnosed with AML are cured. Future improvements are unlikely to come from further increases in chemotherapy intensity. Alternative approaches, such as risk-directed therapy based on different prognostic criteria; differentiation therapy with all-trans-retinoic acid (ATRA, Vesanoid), arsenic trioxide (Trisenox), or azacytidine; and immunotherapy with monoclonal antibodies, tumor vaccines, or cytokines may lead to further advances.

AB - The use of intensive therapy overa brief period of time has produced dramatic improvements in outcome for pediatric patients with acute myelogenous leukemia (AML), as has been demonstrated in studies by the major cooperative groups in the United States and Europe. Still, despite high-intensity chemotherapy and bone marrow transplantation, only about half of the children diagnosed with AML are cured. Future improvements are unlikely to come from further increases in chemotherapy intensity. Alternative approaches, such as risk-directed therapy based on different prognostic criteria; differentiation therapy with all-trans-retinoic acid (ATRA, Vesanoid), arsenic trioxide (Trisenox), or azacytidine; and immunotherapy with monoclonal antibodies, tumor vaccines, or cytokines may lead to further advances.

UR - http://www.scopus.com/inward/record.url?scp=0036675211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036675211&partnerID=8YFLogxK

M3 - Review article

VL - 16

SP - 1057

EP - 1066

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 8

ER -